Guardant Health (GH) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $21.49B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Diagnostics & Research |
| Country | US | CEO | Helmy Eltoukhy |
| IPO Date | 2018-10-04 | CAGR | 50.19% |
| Employees | 2,498 | Website | guardanthealth.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | -0.05% | Total Yield | -0.05% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $20.44B | P/E | -45.88 | Forward P/E | -355.72 | PEG | — |
| P/S | 18.1 | P/B | -95.68 | P/CF | -123.32 | P/FCF | -93.73 |
| Sales | $1.18B | Sales 1Y | 42.74% | Sales 3Y | 131.91% | Sales 5Y | 265.55% |
| EPS | $-3.49 | EPS 1Y | 4.18% | EPS 3Y | -28.92% | EPS 5Y | -7.43% |
| Sales QoQ | 11.04% | EPS QoQ | 5.88% | Sales QoQ Avg | 9.66% | EPS QoQ Avg | 4.63% |
| Gross Margin | 65.01% | Operating Margin | -39.75% | Profit Margin | -38.33% | ROCE | -29.89% |
| ROA | -24% | ROE | 211% | Altman Z Score | 3.8 | Piotroski Score | 4 |
| Current Ratio | 4.03 | Quick Ratio | 3.71 | Cash Ratio | 3.11 | Op. CF Ratio | -0.17 |
| Debt/Equity | -7.49 | Debt/Assets | 0.87 | Lt Debt/Equity | -7.49 | Lt Debt/Cap. | 1.15 |
| Intrst Cov. | 825.02 | Inventory Turnover | 3.93 | Asset Turnover | 0.62 | Receivables Turnover | 8.2 |
| Enterprise Value | $20.44B | P/E Ratio | -45.88 |
| Forward P/E | -355.72 | PEG Ratio | — |
| P/S Ratio | 18.1 | P/B Ratio | -95.68 |
| P/CF Ratio | -123.32 | P/FCF Ratio | -93.73 |
| EPS | $-3.49 | EPS Growth 1Y | 4.18% |
| EPS Growth 3Y | -28.92% | EPS Growth 5Y | -7.43% |
| Revenue Growth 1Y | 42.74% | Gross Margin | 0.65% |
| Operating Margin | -0.4% | Profit Margin | -0.38% |
| ROE | 2.11% | ROA | -0.24% |
| ROCE | -0.3% | Current Ratio | 4.03 |
| Quick Ratio | 3.71 | Cash Ratio | 3.11 |
| Debt/Equity | -7.49 | Interest Coverage | 825.02 |
| Altman Z Score | 3.8 | Piotroski Score | 4 |
Guardant Health (GH) valuation & financials
Guardant Health (GH) has a market capitalization of $21.49B and trades at a price-to-earnings ratio of -45.9. It operates in the Healthcare sector (Medical - Diagnostics & Research).
Guardant Health's revenue grew +42.7% over the last year.
Guardant Health's next earnings report is scheduled for October 28, 2026 after market close; analysts estimate EPS of $-0.28. Check the earnings calendar to see all companies reporting this week.
Guardant Health (GH) — frequently asked questions
When does Guardant Health (GH) report earnings next?
Guardant Health is expected to report earnings on October 28, 2026 after market close. Analysts estimate EPS of $-0.28.
What is Guardant Health's market cap?
Guardant Health (GH) has a market capitalization of $21.49B.
What is GH's P/E ratio?
Guardant Health trades at a price-to-earnings ratio of -45.9, with trailing twelve-month EPS of $-3.49.
How fast is Guardant Health growing?
Guardant Health's revenue grew +42.7% over the last year.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)